pulmonary
(2)
Carbon Biosciences
Carbon Biosciences is a Waltham, Massachusetts preclinical genetic-medicine company building gene therapies on non-AAV parvovirus vectors. Founded by Longwood Fund with gene-therapy pioneers John Engelhardt and Robert Kotin, it uses a proprietary vector engine (PAVE) to design capsids from the broad parvovirus family - including human bocavirus - that carry larger genetic payloads, target specific tissues, and provoke little pre-existing immunity, opening the door to re-dosing. Its lead program targets cystic fibrosis by delivering the full-length CFTR gene to the lung, with a second vector aimed at cardiac disease.
Noel Greenberger
Noel Greenberger is the CEO of Nob Hill Therapeutics, an Albuquerque-based respiratory company building DryNeb, a dry powder nebulizer that pushes high therapeutic doses deep into the lungs regardless of a patient's breathing capacity. A Wharton MBA and Northwestern-trained industrial engineer, he spent years commercializing respiratory medicines at Sandoz, ran commercial strategy at Vertice Pharma, and consulted at McKinsey and ZS Associates before taking the helm of Nob Hill in 2022. Under his watch the company won a $1.73M HHS Phase II grant and closed a $3M Series A in 2024.